Brefonalol (Brefanolol) hydrochloride is an orally active, non-selective β-adrenergic receptor blocker with vasodilatory properties. Brefonalol hydrochloride exhibits an optimal balance between β-blockade and vasodilatory effects at low doses: it reduces blood pressure and slows heart rate, while increasing stroke volume instead of decreasing it, causing no significant elevation in peripheral resistance and increasing reactive hyperemia; at high doses, the β-blockade effect dominates. Brefonalol hydrochloride can be used in the research of arterial hypertension [1].
In Vitro, Brefonalol hydrochloride exhibits balanced β-receptor blocking and vasodilatory effects at a dose of 50 mg, while at a dose of 100 mg, it primarily exerts β-receptor blocking effects[1].
References:
[1]. Halabi A, et al. Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. J Cardiovasc Pharmacol. 1990;16(1):81-86.
In Vitro, Brefonalol hydrochloride exhibits balanced β-receptor blocking and vasodilatory effects at a dose of 50 mg, while at a dose of 100 mg, it primarily exerts β-receptor blocking effects[1].
References:
[1]. Halabi A, et al. Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. J Cardiovasc Pharmacol. 1990;16(1):81-86.